| INTRODUC TI ON
helping curtail the HCV epidemic. 5, 6 Several recent urban ED-based studies provide estimates of the HCV prevalence in ED populations. 5, 6 As yet, however, no studies have described the incidence of HCV infection in the ED populations, information that could be critical for defining ED's future role in the national testing strategy.
Our aim in this study was to estimate the HCV incidence among patients presenting to an urban ED which had an observed HCV seroprevalence of 13.8% in 2013. 6 
| ME THODS
To assess HCV incidence, we conducted a longitudinal chart re- CIs were estimated by mid-p exact test method using R version 3.4.2.
| RE SULTS
Two hundred and ninety-nine of 5039 unique ED patients during the 7-week "index period" were included. HCV incidence and socio-demographic characteristic of these patients are summarized ( 
| D ISCUSS I ON
As the first-ever HCV incidence study conducted in an ED setting,
we found the incidence of HCV infection (3.5/1000 PYs) amongst a subset of this population to be 33-time higher than the incidence in the general US population (0.105), 1 Relevant categories were collapsed to eliminate no incident HCV case in the particular category for the purpose of estimation of incidence ratio. *Mid-p exact test, P < .05.
high-risk groups. 7, 8 In addition, we identified that factors associated with increased risk for acquisition of HCV infection included White race (possibly related to high rates of nondisclosure of IDU in that population), IDU and unknown/unaware of HIV status. We also observed that the incidence of HCV for those born outside of birthcohort (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) was nearly identical to that observed in the CDC-designated "birthcohort" . Together with findings from ours and other previous seroprevalence studies, 6 these data emphasize the extremely high burden of HCV in the ED population, as well as the need to expand existing CDC testing recommendations to include EDs as a venue for testing. Suggested strategies based on our data could include targeted testing in high-risk subgroups, as well as repeat testing (although the exact frequency with which repeat testing should occur requires further study). Unfortunately, the Center for Medicare and Medicaid Services currently specifically exclude reimbursement for ED-based HCV screening, 9 discouraging
EDs to test, and missing critical windows for interventions.
The high HCV incidence in our population coincides with the emerging public health crisis of opioid overdose in Baltimore, where over 600 overdose deaths were reported in 2016 alone. rate. 11, 13 Regarding limitations, this is a single institution study with a small number of seroconversions. In addition, our estimates of incidence are based only on tests within our health system. Finally, as this was a longitudinal chart review study of disease occurrence in patients in the medical care setting, our study could be impacted by the medical surveillance bias when comparing HCV incidence in the general population. Patients included for this study might more likely be those who were perceived to be at increased risk by clinicians, or who presented with HCV-related symptoms, increasing the likelihood that they would have been tested for HCV prior to implementation of our ED-based testing programme in 2015. As this is a retrospective chart review study, ED clinicians were unaware of our study when they ordered an HCV test for patients. This type of potential bias would not have impacted our findings of the higher risk subgroups of patients in whom higher HCV incidence was observed. In spite of these limitations, our study provides the first evidence of alarmingly high HCV incidence in ED patients and should be informative to public health policymakers crucial for devising strategies to augment current HCV testing recommendations.
In summary, in this urban ED, the high HCV incidence in the ED population is comparable to that seen amongst the CDC defined highrisk groups. The relatively higher incidence observed in subgroups, which are each disproportionately affected by the HCV/HIV/opioid epidemics, highlights the potential role that urban EDs could serve as sentinel sites, both for diagnosing HCV and for providing a portal of entry to care. We propose that ED-based bundled interventions for diagnosing HCV and HIV, coupled with identification of persons at risk for opioid use/abuse, could be an important component of the public health strategy for addressing these epidemics which represent ongoing threats to the health of the US population.
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